The size of the Asia Pacific Cardiac Marker Testing Market is expected to grow at 11.7% CAGR from 2021 to 2026. It is projected that the market is valued at USD 0.44 billion in 2021 and is anticipated to reach USD 0.76 billion by 2026.
The incidence of cardiovascular diseases leading to deaths is very high in the Asia Pacific countries, which is estimated to support the market growth in this region. Y-O-Y growth in cardiac diseases, rise in funds from public and private organizations for research and development activities on cardiac markers are likely to drive the market growth in the region. Moreover, ongoing clinical trials for recognizing new cardiac markers are likely to propel the cardiac marker testing market growth. Key strategies by key players to improve their shares and growing demand to promote effective healthcare products are escalating the need for the Asia Pacific Cardiac Marker Testing Market.
Technical issues relevant to sample collection and storage, regulatory problems, and inadequate reimbursement policies are some factors restricting the cardiac marker testing market in the APAC region. The shortage of skilled professionals is hindering the Asia Pacific Cardiac Marker Testing Market demand.
This research report on the Asia Pacific Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories:
By Type:
By Product:
By Disease:
By Testing:
By Country:
Regional Analysis:
Among all the regions of the globe, the Asia Pacific region is expected to grow at the fastest rate during the forecast period due to factors like Y-O-Y growth in CVD incidence in countries like India and China and a quick rise in the aging population. Initiatives taken by the public and private companies to bring out awareness regarding the early disease diagnosis are escalating APAC's market growth. China is expected to rule the market shares because of mounting knowledge about advanced technologies among lab professionals and cardiologists due to continuous conferences and seminars. In China, annual cardiovascular events are evaluated to rise by more than 50% from 2010 to 2030. Japan and India have considerable and notable growth in the cardiac marker testing market in APAC. Factors like improving healthcare infrastructure, large patient count, and growing funds and investments for the enhancements of cardiac analyzers are impelling the APAC region's market growth.
Notable companies leading the Asia Pacific Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Reagents and Kits
5.1.3 Instruments
5.1.3.1 Chemiluminescence
5.1.3.2 Immunofluorescence
5.1.3.3 Elisa
5.1.3.4 Immunochromatography
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Troponin I & T
5.2.3 CK-MB
5.2.4 Myoglobin
5.2.5 BNP
5.2.6 hsCRP
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
5.3 Disease
5.3.1 Introduction
5.3.2 Acute Coronary Syndrome
5.3.3 Myocardial Infarction
5.3.4 Congestive Heart Failure
5.3.5 Y-o-Y Growth Analysis, By Disease
5.3.6 Market Attractiveness Analysis, By Disease
5.3.7 Market Share Analysis, By Disease
5.4 Type of Testing
5.4.1 Introduction
5.4.2 Lab
5.4.3 Point-Of-Care Testing
5.4.4 Y-o-Y Growth Analysis, By Type of Testing
5.4.5 Market Attractiveness Analysis, By Type of Testing
5.4.6 Market Share Analysis, By Type of Testing
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Disease
6.1.3.5 By Type of Testing
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Disease
6.1.4.5 By Type of Testing
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Disease
6.1.5.5 By Type of Testing
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Getinge Group
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Medtronic plc
8.3 LivaNova PLC
8.4 XENIOS Roche Diagnostics Ltd.
8.5 Abbott Laboratories
8.6 Siemens AG
8.7 Danaher Corporation
8.8 Alere Inc.
8.9 BioMérieux SA
8.10 LSI Medience Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
